OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars
Mar 25, 2022 – Clinical
OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).
Feb 10, 2022 – Clinical
OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..
Nov 9, 2021 – Clinical
OTR3 starts a post market clinical follow up on Cacipliq 20®.
Oct 8, 2021 – Clinical
OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.
Aug 25, 2021 – Financial
OTR3 receives a state guaranteed loan amounting to € 0.5 m.
Jun 29, 2021 – Corporate
OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.